Business Context and Reporting Period
Company: Actinium Pharmaceuticals, Inc. (ATNM)
Filing Type: Form 8-K (Current Report)
Date of Report: June 16, 2020
Event: Commencement and pricing of a public offering of common stock and pre-funded warrants.
Key Financial Metrics
This filing details a capital raise rather than periodic operating results. Key financial figures related to the transaction include:
- Offering Size: 76,923,077 total units (55,653,846 shares of Common Stock and pre-funded warrants for 21,269,231 shares).
- Offering Price: $0.3250 per share/unit.
- Expected Net Proceeds: Approximately $22.8 million (after deducting placement agent fees and estimated offering expenses).
- Placement Agent Fees: 7.0% of aggregate gross proceeds plus reimbursement for expenses (up to $137,900 in legal and clearing fees plus a $25,000 expense allowance).
- Pre-funded Warrant Exercise Price: $0.0001 per share.
Note: The filing does not provide current revenue, profit, cash flow, or debt levels as this is a transaction report, not a quarterly or annual financial statement.
Material Changes and Transaction Details
The primary material change is the dilution of existing shareholders and the influx of capital via the Offering. Key terms include:
- Structure: The offering consists of direct shares and pre-funded warrants, which are immediately exercisable.
- Ownership Limits: Holders of pre-funded warrants are restricted from exercising to own more than 4.99% (or 9.99% at election) of outstanding shares immediately after exercise, unless 61 days' prior notice is given to increase ownership up to 9.99%.
- Lock-up Provisions: The Company agreed not to issue additional common stock or equivalents for 30 days post-closing and agreed not to enter into variable rate transactions for six months post-closing.
- Closing Date: Expected on or about June 19, 2020.
Outlook, Management Commentary, and Use of Proceeds
Management intends to utilize the net proceeds of approximately $22.8 million for the following strategic initiatives:
- Lead Product (Iomab-B): Complete the pivotal Phase 3 SIERRA trial, prepare and submit a Biologics License Application (BLA) to the FDA, and submit a Marketing Authorization Application to the European Medicines Agency. Funds will also support U.S. commercialization activities.
- CD33 Program: Progress Phase 1 trials to the proof of concept stage.
- Platform and R&D: Support the AWE Technology Platform, the Iomab-ACT program, and general research and development.
- Working Capital: General corporate needs.
Investor Verification Checklist
- Verify the final closing date of the Offering (expected June 19, 2020) and the actual net proceeds received.
- Review the updated share count and dilution impact on existing shareholders post-closing.
- Monitor the progress of the Phase 3 SIERRA trial for Iomab-B as the primary use of funds.
- Check for any subsequent filings regarding the exercise of pre-funded warrants or changes in the 30-day/6-month lock-up restrictions.
- Confirm the status of the Biologics License Application (BLA) submission timeline.